Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that Seth Lederman, MD, Chief Executive Officer, ...

Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum

Tonix Pharma Q4 earnings: revenue up 109% on early Tonmya launch, but losses persist. Click here to read my most recent analysis of TNXP stock.

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO) and Tonix Pharma (TNXP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jade Biosciences (JBIO – Research Report) and Tonix Pharma (TNXP – Research Re ...

Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch

Tonix Pharmaceuticals beats expectations, and Tonmya prescriptions grow, with over 4,200 prescriptions since launch.
Stocktwits on MSN

TNXP stock rises premarket: Investors cheer early traction for fibromyalgia drug despite weak Q4 print

CEO Seth Lederman said early trends show favorable prescriber uptake and repeat utilization. ・Investors are also watching TNX ...

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through ...